The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of weekly irinotecan and carboplatin for relapsed ovarian cancer: A Kansai Clinical Oncology Group study.
H. Tsubamoto
No relevant relationships to disclose
K. Inoue
No relevant relationships to disclose
R. Kawaguchi
No relevant relationships to disclose
K. Ito
No relevant relationships to disclose
S. Takeuchi
No relevant relationships to disclose
T. Shiozaki
No relevant relationships to disclose
Y. Itani
No relevant relationships to disclose
A. Arakawa
No relevant relationships to disclose
T. Tabata
No relevant relationships to disclose
S. Toyoda
No relevant relationships to disclose